dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· June 17, 2026

Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally

View original at globenewswire.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber are collaborating to develop and deploy L4 driverless mobility services By combining Stellantis’ world-class vehicle L4-Ready Platforms™, Wayve’s advanced AI Driver…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Successfully scaling autonomous mobility requires seamlessly combining the right vehicles, technology, and platform.

    60% confidence
  • Uber has completed more than 75 billion trips since its founding in 2010.

    60% confidence
  • The three-way partnership signals industry convergence around Wayve's technology as the leading approach to scale autonomous vehicles globally.

    60% confidence
  • The collaboration will deliver smarter, safer, and more efficient mobility by combining Stellantis' L4-Ready Platforms with Wayve's adaptive AI and Uber's global network to accelerate AV deployment that meets real customer needs at scale.

    60% confidence
  • Wayve's AI driving technology is designed to adapt across different regions and driving conditions without relying on city-by-city mapping or re-engineering, enabling faster and more cost-effective expansion.

    60% confidence

Data points we hold from this source

Uber Technologies · trips completed75 billion_trips
Uber Technologies · founding year2010 year
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,995
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,995 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally: Source | Via News | fr.via.news